GGGlorimar Guzmán-Pérez

Glorimar Guzmán-Pérez

*This is an algorithmically generated author record based on publicly available information.

Glorimar Guzmán-Pérez has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mechanistic and preclinical evaluation of SIRT3 as a therapeutic target in melanoma

    by Karla B. Anaya Aldrete, Mary A. Ndiaye, Glorimar Guzmán-Pérez, Gabriella R. Zaemisch, Chandra K. Singh, Gagan Chhabra, Nihal Ahmad

    Melanoma, arising from pigment-producing cells (melanocytes) in the skin, is one of the deadliest skin cancers due to its tendency to metastasize and its resistance to existing therapies. In the Un...


  • Antimelanoma Effects of Concomitant Inhibition of SIRT1 and SIRT3 in Braf/Pten Mice

    by Gagan Chhabra, Chandra K. Singh, Glorimar Guzmán-Pérez, Mary A. Ndiaye, Kenneth A. Iczkowski, Nihal Ahmad


  • CRISPR/Cas9‐mediated Knockout of SIRT6 Imparts Remarkable Antiproliferative Response in Human Melanoma Cells in vitro and in vivo

    by Liz M. Garcia‐Peterson, Mary A. Ndiaye, Gagan Chhabra, Chandra K. Singh, Glorimar Guzmán‐Pérez, Kenneth A. Iczkowski, Nihal Ahmad

    Melanoma is one of the most aggressive, potentially fatal forms of skin cancer and has been shown to be associated with solar ultraviolet radiation‐dependent initiation and progression. Despite remarkable recent advances with targeted and immune therapeutics, lasting and recurrence‐free survival remain significant concerns. Therefore, additional novel mechanism‐based approaches are needed for effective melanoma management. The sirtuin SIRT6 appears to have a pro‐proliferative function in melanocytic cells. In this study, we determined the effects of genetic manipulation of SIRT6 in human melanoma cells, in vitro and in vivo . Our data demonstrated that CRISPR/Cas9‐mediated knockout (KO) of SIRT6 in A375 melanoma cells resulted in a significant (1) decrease in growth, viability and clonogenic survival and (2) induction of G1‐phase cell cycle arrest. Further, employing a RT2 Profiler PCR array containing 84 key transformation and tumorigenesis genes, we found that SIRT6 KO resulted in modulation of genes involved in angiogenesis, apoptosis, cellular senescence, epithelial‐to‐mesenchymal transition, hypoxia signaling and telomere maintenance. Finally, we found significantly decreased tumorigenicity of SIRT6 KO A375 cells in athymic nude mice. Our data provide strong evidence that SIRT6 promotes melanoma cell survival, both in vitro and in vivo, and could be exploited as a target for melanoma management.


  • Open Access

    The sirtuin 6: An overture in skin cancer

    by Liz M. Garcia‐Peterson, Glorimar Guzmán‐Pérez, Cassandre R. Krier, Nihal Ahmad

    In the recent past, the sirtuins have been under intense investigation for their roles in biology and disease, including cancer. The sirtuin SIRT6 is comparatively a lesser studied member of this family of seven proteins. Like certain other sirtuins, SIRT6 is emerging to have an oncogenic function as well as tumor suppressor roles in cancer. Limited studies have been conducted assessing the role and functional significance of SIRT6 in melanoma and non-melanoma skin cancers. In this review, we have attempted to critically dissect the potential role and significance of SIRT6 in skin carcinogenesis. With limited available information to date, SIRT6 appears to have a pro-proliferative function in non-melanoma skin cancers (NMSCs), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). In addition, SIRT6 is also emerging to have an oncogenic function in melanoma. Moreover, we have provided information regarding the available SIRT6 inhibitors. Conclusively, it appears that additional comprehensive studies are needed to establish the role of SIRT6 in skin biology and skin diseases, including cancer. Further, concerted efforts are needed to characterize the stage-specific role of SIRT6 in skin cancers.